Provided by Tiger Trade Technology Pte. Ltd.

PTC Therapeutics

65.30
-1.7750-2.65%
Post-market: 65.300.00000.00%18:04 EDT
Volume:2.02M
Turnover:132.32M
Market Cap:5.41B
PE:8.39
High:68.20
Open:68.00
Low:65.10
Close:67.08
52wk High:87.50
52wk Low:35.95
Shares:82.77M
Float Shares:72.98M
Volume Ratio:1.72
T/O Rate:2.76%
Dividend:- -
Dividend Rate:- -
EPS(TTM):7.78
EPS(LYR):7.78
ROE:-7740.12%
ROA:23.26%
PB:-26.33
PE(LYR):8.39

Loading ...

Analysts Offer Insights on Healthcare Companies: PTC Therapeutics (PTCT), Revolution Medicines (RVMD) and West Pharmaceutical Services (WST)

TIPRANKS
·
Jan 13

PTC Therapeutics: Sephience Outperformance and Votoplam De‑Risking Drive Upgraded Medium-Term Growth Outlook and Buy Rating

TIPRANKS
·
Jan 13

Wave of Insider Moves as PTC Therapeutics Leaders Cash In on Company Stock

TIPRANKS
·
Jan 13

Christine Marie Utter, SVP and Chief Accounting Officer, Reports Disposal of PTC Therapeutics Inc. Common Shares

Reuters
·
Jan 13

PTC Therapeutics Exec VP and CLO Mark Elliott Boulding Reports Sale of Common Shares

Reuters
·
Jan 13

PTC Therapeutics Posts Strong 2025 Results, Updates 2026 Outlook

TIPRANKS
·
Jan 13

BRIEF-Ptc Therapeutics Provides Update At J.P. Morgan Annual Healthcare Conference

Reuters
·
Jan 12

PTC Therapeutics forecasts 2026 product revenue of $700 to $800 million

Reuters
·
Jan 12

PTC Therapeutics Inc - Sephience Launch Continues With Unaudited Q4 Global Revenue of $92.5M

THOMSON REUTERS
·
Jan 12

PTC Therapeutics Inc - 2026 Product Revenue Guidance of $700 – 800M

THOMSON REUTERS
·
Jan 12

PTC Therapeutics Provides Update at J.p. Morgan Annual Healthcare Conference

THOMSON REUTERS
·
Jan 12

Wave of Insider Selling Sweeps Through PTC Therapeutics’ Executive Ranks

TIPRANKS
·
Jan 09

PTC Therapeutics CFO Pierre Gravier Reports Disposal of Common Shares

Reuters
·
Jan 09

PTC Therapeutics Grants 300 RSUs to New Hire Under Nasdaq Inducement Rule

Reuters
·
Jan 09

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jan 09

RBC Lowers Price Target on PTC Therapeutics to $87 From $91, Keeps Sector Perform Rating

MT Newswires Live
·
Jan 08

PTC Therapeutics Director Glenn Steele Jr. MD PhD Reports Disposal of Common Shares

Reuters
·
Jan 07

PTC Therapeutics CEO Matthew B. Klein Reports Sale of Common Shares

Reuters
·
Jan 03

It’s Earnings Warning Season. How to Profit From Others’ Misery

Dow Jones
·
Jan 01

What's Going On With Royalty Pharma Stock Wednesday?

Benzinga
·
Dec 31, 2025